1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
664C679381ADDFEBF0025881600600A42
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/hcp-engagement-excellence-optimizing-contracting-processes-efficiency?opendocument
18
19opendocument
2035.175.107.185
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Thought Leader Services

HCP Engagement Excellence: Optimizing Contracting Processes and Efficiency

ID: 5722


Features:

16 Info Graphics

13 Data Graphics

230+ Metrics

24 Narratives


Pages/Slides: 34


Published: 2022


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "HCP Engagement Excellence: Optimizing Contracting Processes and Efficiency"


STUDY OVERVIEW


Medical biopharmaceutical groups engage with Healthcare Practitioners (HCPs) for a variety of critical activities that require contracts between pharma and the HCP.

But it take months for the two sides to navigate pharma companies’ internal contracting process, especially for EU-based HCPs. Some organizations have designed streamlined internal steps for their HCP contracting process that gives them a competitive advantage over their more cumbersome peers.

This new Best Practices, LLC study informs medical groups on HCP contracting processes, effectiveness and timelines for engaging HCPs. The research study will enable medical operations leaders to see how their company’s HCP contracting approach compares with industry peers on key issues affecting the efficiency and speed of HCP engagement.

KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • HCPs Engagement Programs and Geographic Perspective
  • HCP Engagement Contracting Process

KEY METRICS

I. HCPs Engagement Programs and Geographic Perspective

  • Functional orientation of HCP engagement programs and Types of medical and/or commercial programs that external HCPs are utilized for
  • Geographic representation of the contracted HCPs

II. HCP Engagement Contracting Process

  • Effectiveness of benchmark companies’ contracting process for engaging HCPs (advisory boards, consulting, etc.)
  • Interview narrative around driving HCP contracting effectiveness in EU
  • Average time taken from program approval to program execution for the types of HCP contracting listed
  • Interview narrative around lead time required for executing HCP contracts in various countries
  • Interview narrative around EU HCP contracting challenges
  • Steps used as part of the HCP pre-contracting process for the types of HCP contracting listed
  • Steps used as part of the HCP post-contracting process for the types of HCP contracting listed
  • Average HCP contracting process timeline for global US contracting for EU and optimal timeline for the same
  • Interview narrative around complications surrounding EU contracting
  • Average HCP contracting process timeline for global US contracting outside EU/US and optimal timeline for the same
  • Benchmark success at reducing complexities that are/were inherent in the HCP engagement contracting process
  • Tactics for reducing HCP engagement contracting complexities
  • Partner narratives around how they reduced contracting complexities
  • Interview narrative around the use of templates for HCP engagements
  • Interview narrative around accelerating the HCP contracting process
  • Interview narrative around having a flexible HCP contract
  • Interview narrative around the use of master service agreements


SAMPLE KEY FINDINGS

  • 40% think their HCP contracting process is effective in the US and EU
  • Global US contracting for EU takes longer than US and O-EU/US contracting

METHODOLOGY

Best Practices, LLC engaged 20 leaders from 20 organizations for this study. Deep-dive interviews were also conducted with four leaders to capture their insights about HCP contracting.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Manufacturing; Consumer Products; Diagnostic; Medical Device; Communications; Biopharmaceutical


Companies Profiled:
AbbVie; Merck Serono; Amgen; Pfizer; Takeda Pharmaceuticals; Sandoz; Baxter BioScience; Eisai; Ipsen; Bayer; UCB Pharma; Medexus Pharmaceuticals; Kyowa Kirin; Eurofarma; Jazz Pharmaceuticals; NexGen Healthcare; Apellis Pharmaceuticals; Fidia; Heron Therapeutics; Imbrium Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.